ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2026
Comparison between DNA- and RNA-based nucleic acid amplification tests for detecting Mycoplasma pneumoniae in pediatric specimens.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of doxycycline treatment with time to first documented MP-RNA negative conversion in pediatric Mycoplasma pneumoniae pneumonia: a retrospective cohort study.Italian journal of pediatrics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMycoplasma pneumoniae, a globally prevalent cause of community-acquired pneumonia in children and young adults, is typically diagnosed using molecular methods, including DNA- or RNA-based nucleic acid amplification tests (NAATs). While RNA-based NAAT is considered to reflect the viability and replication status of M. pneumoniae, a direct comparison of the clinical performance between DNA- and RNA-based NAATs has been lacking. This study aimed to compare these NAATs in clinical pediatric M. pneumoniae samples and elucidate the reasons for their differential detection outcomes.
methodsThis study analyzed clinical M. pneumoniae samples from pediatric patients across different sample types, seasons, age, and sex subgroups between January and December 2018. The underlying reasons for their differential detection outcomes were further elucidated through in vitro culture and cell infection models.
resultsA total of 3180 clinical samples were analyzed. The performance of DNA- and RNA-based NAATs showed specific disparities, particularly associated with sample type and patient age, but not with sampling season or patient sex. In vitro experiments revealed that M. pneumoniae-RNA (MP-RNA) has higher synthesis and degradation rates, whereas M. pneumoniae-DNA (MP-DNA) accumulates and is sustained longer in the growth dynamics of the pathogen.
conclusionThe differential nucleic acid kinetics of M. pneumoniae across respiratory microenvironments likely explain the observed variations in clinical detection. These findings may enable evidence-based selection of DNA- or RNA-based NAATs according to patient age and sample type, thereby improving the reliable detection of M. pneumoniae in children.
Indexed as
Identifiers
41764110What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.